News Overview


Two of PARK INNOVAARE start-ups were on the top 100 list last year: InterAx Biotech AG and Nomoko AG. ©Digital Switzerland
Two of PARK INNOVAARE start-ups were on the top 100 list last year: InterAx Biotech AG and Nomoko AG. ©Digital Switzerland

Did you like this article? Please share it.



Each year, launches the TOP 100 STARTUP AWARD. From over 100,000 young companies, the 100 most innovative and promising Swiss start-ups are picked by top start-up experts. The ranking is a great opportunity for young companies to assert themselves and to meet investors. This year, four PARK INNOVAARE start-ups – GratXray AG, InterAx Biotech AG, Nomoko AG, and novoMOF AG – are running for the award.

Switzerland ranks as the most innovative nation according to the Global Innovation Index 2017. The TOP 100 Swiss technological startups selected by leading experts give a good flavor as to why this is the case. Their profiles, selected by start-up experts (from business angel networks, investor platforms, coaching programs etc.) and through an open vote, will be published in a special edition of the Handelszeitung, the most renowned Swiss business and economy weekly newspaper and as such an important source of information for many Swiss investors.

This year, four companies from PARK INNOVAARE’s ecosystem have a chance to become one of the top 100 Swiss most promising start-ups and to compete for the award:

GratXray AG is an innovative medical device company, developing, producing systems based on phase contrast enhanced X-ray imaging. Their worldwide patented method is ideal for soft tissue imaging, as it provides unprecedented density contrast and tissue delineation in low absorbing tissues. The company focuses on applications, where classic X-ray systems fail or provide unsatisfied results: for example, breast cancer.

InterAx Biotech AG, a spin-off from the ETH Zurich and the Paul Scherrer Institute (PSI), is building a unique drug discovery platform for identification of functionally selective G protein-coupled receptor (GPCRs) drug candidates. Its unique drug discovery platform will dramatically reduce costs for the development of novel GPCR drugs with reduced side effects, thereby benefiting patients with unmet medical needs.

novoMOF AG is a technology company in the field of advanced materials with focus on synthesis and production of metal-organic frameworks (MOF). MOFs are novel materials that offer competitive applications in various industrial sectors. For instance, charging times of batteries can be reduced to minutes, the lifetime of packaged food can be prolonged or gases such as carbon dioxide can be separated, purified or stored.

Nomoko AG is developing the platform to interact and build applications on top of the digital twin of the world – a photorealistic 3D models of entire cities with dynamic agents and contextual information. To achieve their goal, the team is building a gigapixel camera and a high performance, distributed 3D pipeline. Nomoko’s technology will help accelerating the development of the production-ready self-driving car.

Support our start-ups! Vote for them at here! You are only allowed to vote for one start-up.